checkAd

Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity

Nachrichtenagentur: news aktuell
17.05.2021, 16:15  |  143   |   |   

Darmstadt, Germany (ots/PRNewswire) - - Merck to support up to six additional
research projects at the BioMed X Institute in Heidelberg within the next six
years

- Call for application for a global crowdsourcing project, 'Regulatory T Cell
Dysfunction in Autoimmunity and Inflammaging'

Handeln Sie Ihre Einschätzung zu Merck KGaA!
Long
Basispreis 143,53€
Hebel 13,30
Ask 0,92
Short
Basispreis 165,09€
Hebel 12,32
Ask 1,34

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

Merck, a leading science and technology company, today announced the extension
of its ongoing collaboration with BioMed X, Heidelberg, Germany. Under the new
agreement, Merck will start up to six additional research projects at the BioMed
X Institute, building on ongoing research projects in the fields of oncology
(DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial
barrier in autoimmune diseases). The next joint global crowdsourcing project
will explore mechanisms of immune senescence and mitochondrial dysfunction in
regulatory T cells and other T cell subsets that are shared in human
autoimmunity and aging.

"We are excited to strengthen our ongoing commitment to our partnership with
BioMed X," said Joern-Peter Halle, Global Head of Research at the Healthcare
business of Merck. "As a result of this successful collaboration, multiple
innovative discovery projects in new research areas have been started at Merck,
including the successful implementation of our open innovation concept
'outcubation' published in Nature Biotechnology
(https://www.nature.com/articles/nbt.3112?foxtrotcallback=true) , and we look
forward to the scientific advances to come."

Merck was the first pharma company to enter a partnership with BioMed X,
beginning in 2013. Since then, the partnership has steadily grown and the
previously initiated research projects have led to 25 scientific publications
(https://bio.mx/newsroom/scientific-publications/) on topics such as in-silico
design of selective kinase inhibitors, myeloid-derived suppressor cell activity,
Golgi stress, and DNA damage, as well as several new potential drug target genes
which have been further investigated in pre-clinical studies at Merck.

The new research projects will build on this ongoing work, as well as BioMed X's
expertise in the fields of immunology and inflammation and Merck's in-house
discovery capabilities in oncology, immuno-oncology and immunology.

"We are very grateful for the trust and support we received from Merck over the
past eight years since we started our collaboration," Christian Tidona, Founder
and Managing Director of the BioMed X Institute said. "This new agreement with
Merck is a great validation of our unique innovation model, showing that it
delivers sustained translational value to the early R&D pipelines of our pharma
partners."

Candidates interested in the latest call for proposals in the area of immune
Seite 1 von 2
Merck Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity - Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years - Call for application for a global crowdsourcing project, 'Regulatory T Cell Dysfunction in Autoimmunity and …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel